|1.||Labrie, Fernand: 29 articles (12/2015 - 03/2003)|
|2.||Weizman, Abraham: 23 articles (10/2013 - 01/2003)|
|3.||Maayan, Rachel: 23 articles (07/2011 - 01/2003)|
|4.||Martel, Céline: 15 articles (12/2015 - 09/2008)|
|5.||Strous, Rael D: 12 articles (01/2010 - 02/2003)|
|6.||Cusan, Leonello: 11 articles (12/2015 - 10/2003)|
|7.||Labrie, Claude: 11 articles (09/2015 - 04/2003)|
|8.||Arnold, Julia T: 11 articles (11/2013 - 03/2005)|
|9.||Côté, Isabelle: 10 articles (12/2015 - 09/2008)|
|10.||Lavoie, Lyne: 10 articles (12/2015 - 09/2009)|
11/01/1997 - "Many of his symptoms improved on DHEA therapy, but his cancer also flared dramatically during treatment. "
01/01/2008 - "Thus, it is possible to detect unrecognized serious heart conditions or early-stage cancer that are currently present or that were present in the recent past by examining the white hairs of the eyebrows, and these diseases can be improved by one optimal dose of DHEA or Astragalus."
11/01/1995 - "Analysis of multiplicity of total tumors of any category revealed comparable values for DHEA and control groups, while the IM group showed a significant reduction. "
07/01/1998 - "This preliminary study would suggest there to be a deficiency in the daily DHEA secretion in patients with disseminated cancer. "
08/01/1997 - "In view of the almost exclusive periportal localization of DHEA-induced tumors in female rats in contrast to the pericentral localization of the peroxisomal proliferation shown by this study, it seems likely that other factors in addition to peroxisome proliferation may contribute to the hepatocarcinogenic effect of DHEA."
06/01/1992 - "Hamsters treated with DHEA exhibited a significant reduction in cryptosporidial infection when compared to untreated hamsters. "
04/15/1992 - "Both DHEA and AED appear to function by facilitating and upregulating host immune responses via mobilization of cutaneous immunity to obtain systemic protection against infections. "
04/15/1992 - "Our previous results have shown that SC injection of DHEA resulted in upregulation of the specific host immune response resulting in protection against a lethal infection. "
05/31/2008 - "In a previous study, we reported that administration of DHEA significantly decreased the numbers of blood parasites in Trypanosoma cruzi experimental infection. "
06/01/2007 - "In the present study, we investigated the effects of DHEA treatment during the acute phase of experimental Trypanosoma cruzi infection. "
|3.||Systemic Lupus Erythematosus (Libman-Sacks Disease)
02/01/2003 - "Treatment with dehydroepiandrosterone was effective in randomized controlled trials in patients with systemic lupus erythematosus. "
11/01/2002 - "Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial."
07/01/2002 - "Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial."
07/01/2014 - "In systemic lupus erythematosus, DHEA is steroid-sparing. "
08/01/2008 - "Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy."
07/01/2010 - "High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy."
01/01/2015 - "Dehydroepiandrosterone administered intravaginally on a daily basis is an effective treatment for symptoms, and signs of vulvovaginal atrophy along with libido in postmenopausal women. "
01/01/2015 - "Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy."
05/01/2015 - "Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study."
09/01/2011 - "In addition studies regarding the effects of vaginal DHEA on sexual function in women without vaginal atrophy are needed. "
03/01/2008 - "These findings suggest that reduced levels of the neurosteroid DHEAS may contribute to fatigue in patients with PBC; substitutive therapy using DHEAS or its precursor DHEA could be beneficial in the management of fatigue in patients with low levels of DHEAS."
01/01/2000 - "In conclusion, DHEA may be a promising treatment for HIV+ patients with depressed mood and fatigue, although persistence of response even in placebo-treated patients during the discontinuation phase leaves unresolved questions. "
06/01/2010 - "Patients from the DHEA and placebo group improved on general fatigue (p<0.001) and mental well-being (p=0.04). "
01/15/2010 - "In an intent-to-treat analysis, a 50-mg DHEA substitution dose and placebo similarly improved fatigue. "
01/01/2008 - "Patients from both the DHEA- and placebo-treated group improved on general fatigue (p<0.001), mental well-being (p = 0.04), and depressive mood (p = 0.008). "
|2.||Activities of Daily Living (ADL)
|3.||Estrogen Replacement Therapy